CRYOPORT, INC. Net Income (Loss) Available to Common Stockholders, Basic
CRYOPORT, INC. (CYRX) reported Net Income (Loss) Available to Common Stockholders, Basic of -$10.26 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-06
- CRYOPORT, INC. net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was -$10.26M, a 109.60% decline year-over-year.
- CRYOPORT, INC. net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was -$12.54M.
- CRYOPORT, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was -$13.64M.
- CRYOPORT, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was -$8.94M.
- CRYOPORT, INC. net income (loss) available to common stockholders, basic for fiscal 2025 was $70.30M.
- CRYOPORT, INC. net income (loss) available to common stockholders, basic for fiscal 2024 was -$122.76M.
- CRYOPORT, INC. net income (loss) available to common stockholders, basic for fiscal 2023 was -$107.59M.
- CRYOPORT, INC. net income (loss) available to common stockholders, basic for fiscal 2022 was -$45.33M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$10.26M 10-Q · filed 2026-08-06 | -$22.80M 10-Q · filed 2026-08-06 | -$36.44M derived: sum of 3 quarters · filed 2026-08-06 | -$45.39M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2026-03-31 | -$12.54M 10-Q · filed 2026-05-05 | -$26.19M derived: sum of 2 quarters · filed 2026-05-05 | -$35.13M derived: sum of 3 quarters · filed 2026-05-05 | $71.74M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-12-31 | -$13.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$22.59M derived: sum of 2 quarters · filed 2026-03-05 | $84.28M derived: sum of 3 quarters · filed 2026-08-06 | $70.30M 10-K · filed 2026-03-05 | ||
| 2025-09-30 | -$8.94M 10-Q · filed 2025-11-06 | $97.93M derived: sum of 2 quarters · filed 2026-08-06 | $83.94M 10-Q · filed 2025-11-06 | $63.27M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-06-30 | $106.87M 10-Q · filed 2026-08-06 | $103.18M 10-Q · filed 2025-08-12 | $92.89M 10-Q · filed 2026-08-06 | $89.20M 10-Q · filed 2025-08-12 | $72.21M derived: sum of 3 quarters · filed 2026-08-06 | $71.02M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$13.98M 10-Q · filed 2026-05-05 | -$34.66M derived: sum of 2 quarters · filed 2026-05-05 | -$35.85M derived: sum of 3 quarters · filed 2026-05-05 | -$115.84M derived: sum of 4 quarters · filed 2026-05-05 | ||
| 2024-12-31 | -$20.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$21.87M derived: sum of 2 quarters · filed 2026-03-05 | -$101.86M derived: sum of 3 quarters · filed 2026-03-05 | -$122.76M 10-K · filed 2026-03-05 | ||
| 2024-09-30 | -$1.20M 10-Q · filed 2025-11-06 | -$81.18M derived: sum of 2 quarters · filed 2025-11-06 | -$102.08M 10-Q · filed 2025-11-06 | -$166.47M derived: sum of 4 quarters · filed 2026-03-05 | ||
| 2024-06-30 | -$79.99M 10-Q · filed 2025-08-12 | -$100.88M 10-Q · filed 2025-08-12 | -$165.27M derived: sum of 3 quarters · filed 2026-03-05 | -$180.54M derived: sum of 4 quarters · filed 2026-03-05 | ||
| 2024-03-31 | -$20.89M 10-Q · filed 2025-05-08 | -$85.28M derived: sum of 2 quarters · filed 2026-03-05 | -$100.55M derived: sum of 3 quarters · filed 2026-03-05 | -$120.91M derived: sum of 4 quarters · filed 2026-03-05 | ||
| 2023-12-31 | -$64.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$79.66M derived: sum of 2 quarters · filed 2026-03-05 | -$100.01M derived: sum of 3 quarters · filed 2026-03-05 | -$107.59M 10-K · filed 2026-03-05 | ||
| 2023-09-30 | -$15.27M 10-Q · filed 2024-11-07 | -$35.62M derived: sum of 2 quarters · filed 2024-11-07 | -$43.20M 10-Q · filed 2024-11-07 | -$54.63M derived: sum of 4 quarters · filed 2024-11-07 | ||
| 2023-06-30 | -$20.36M 10-Q · filed 2024-08-08 | -$27.93M 10-Q · filed 2024-08-08 | -$39.37M derived: sum of 3 quarters · filed 2024-08-08 | -$46.68M derived: sum of 4 quarters · filed 2024-08-08 | ||
| 2023-03-31 | -$7.57M 10-Q · filed 2024-05-08 | -$19.01M derived: sum of 2 quarters · filed 2024-05-08 | -$26.33M derived: sum of 3 quarters · filed 2024-05-08 | -$37.50M derived: sum of 4 quarters · filed 2024-05-08 | ||
| 2022-12-31 | -$11.44M 10-K · filed 2023-02-28 | -$18.75M derived: sum of 2 quarters · filed 2023-11-09 | -$29.93M derived: sum of 3 quarters · filed 2023-11-09 | -$45.33M 10-K · filed 2025-03-07 | ||
| 2022-09-30 | -$7.32M 10-Q · filed 2023-11-09 | -$18.49M derived: sum of 2 quarters · filed 2023-11-09 | -$33.90M 10-Q · filed 2023-11-09 | -$295.98M derived: sum of 4 quarters · filed 2023-11-09 | ||
| 2022-06-30 | -$11.18M 10-Q · filed 2023-08-09 | -$26.58M 10-Q · filed 2023-08-09 | -$288.67M derived: sum of 3 quarters · filed 2023-08-09 | -$297.19M derived: sum of 4 quarters · filed 2023-08-09 | ||
| 2022-03-31 | -$15.40M 10-Q · filed 2023-05-04 | -$277.49M derived: sum of 2 quarters · filed 2023-05-04 | -$286.02M derived: sum of 3 quarters · filed 2023-05-04 | -$293.40M derived: sum of 4 quarters · filed 2023-05-04 | ||
| 2021-12-31 | -$262.09M 10-K · filed 2023-02-28 | -$270.61M derived: sum of 2 quarters · filed 2023-02-28 | -$278.00M derived: sum of 3 quarters · filed 2023-02-28 | -$283.72M 10-K · filed 2024-03-13 | ||
| 2021-09-30 | -$8.53M 10-K · filed 2023-02-28 | -$15.91M derived: sum of 2 quarters · filed 2023-02-28 | -$21.64M 10-Q · filed 2022-11-04 | -$75.50M derived: sum of 4 quarters · filed 2023-02-28 | ||
| 2021-06-30 | -$7.39M 10-K · filed 2023-02-28 | -$13.11M 10-Q · filed 2022-08-04 | -$66.98M derived: sum of 3 quarters · filed 2023-02-28 | -$78.40M derived: sum of 4 quarters · filed 2023-02-28 | ||
| 2021-03-31 | -$5.72M 10-K · filed 2023-02-28 | -$59.59M derived: sum of 2 quarters · filed 2023-02-28 | -$71.01M derived: sum of 3 quarters · filed 2023-02-28 | -$76.81M derived: sum of 4 quarters · filed 2023-02-28 | ||
| 2020-12-31 | -$53.87M 10-K · filed 2023-02-28 | -$65.28M derived: sum of 2 quarters · filed 2023-02-28 | -$71.09M derived: sum of 3 quarters · filed 2023-02-28 | -$75.03M 10-K · filed 2023-02-28 | ||
| 2020-09-30 | -$11.42M 10-K · filed 2023-02-28 | -$17.22M derived: sum of 2 quarters · filed 2023-02-28 | -$21.16M 10-Q · filed 2021-11-04 | -$22.11M derived: sum of 4 quarters · filed 2023-02-28 | ||
| 2020-06-30 | -$5.80M 10-K · filed 2023-02-28 | -$9.75M 10-Q · filed 2021-08-06 | -$10.69M derived: sum of 3 quarters · filed 2023-02-28 | -$23.16M derived: sum of 4 quarters · filed 2023-02-28 | ||
| 2020-03-31 | -$3.94M 10-K · filed 2023-02-28 | -$4.89M derived: sum of 2 quarters · filed 2023-02-28 | -$17.36M derived: sum of 3 quarters · filed 2023-02-28 | -$19.89M derived: sum of 4 quarters · filed 2023-02-28 | ||
| 2019-12-31 | -$948.00K 10-K · filed 2022-02-28 | -$13.42M derived: sum of 2 quarters · filed 2022-02-28 | -$15.95M derived: sum of 3 quarters · filed 2022-02-28 | -$18.33M 10-K · filed 2022-02-28 | ||
| 2019-09-30 | -$12.47M 10-K · filed 2022-02-28 | -$15.00M derived: sum of 2 quarters · filed 2022-02-28 | -$17.38M derived: sum of 3 quarters · filed 2022-02-28 | |||
| 2019-06-30 | -$2.53M 10-K · filed 2022-02-28 | -$4.92M derived: sum of 2 quarters · filed 2022-02-28 | ||||
| 2019-03-31 | -$2.39M 10-K · filed 2022-02-28 | |||||
| 2017-12-31 | -$2.27M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | -$4.25M derived: sum of 2 quarters · filed 2018-03-08 | -$6.11M derived: sum of 3 quarters · filed 2018-03-08 | -$7.90M 10-K · filed 2018-03-08 | ||
| 2017-09-30 | -$1.98M 10-Q · filed 2017-11-02 | -$3.84M derived: sum of 2 quarters · filed 2017-11-02 | -$5.63M 10-Q · filed 2017-11-02 | -$9.91M derived: sum of 4 quarters · filed 2018-03-08 | ||
| 2017-06-30 | -$1.86M 10-Q · filed 2017-08-09 | -$3.65M 10-Q · filed 2017-08-09 | -$7.93M derived: sum of 3 quarters · filed 2018-03-08 | -$10.12M derived: sum of 4 quarters · filed 2018-03-08 | ||
| 2017-03-31 | -$1.79M 10-Q · filed 2017-05-04 | -$6.07M derived: sum of 2 quarters · filed 2018-03-08 | -$8.26M derived: sum of 3 quarters · filed 2018-03-08 | -$12.19M derived: sum of 4 quarters · filed 2018-03-08 | ||
| 2016-12-31 | -$4.28M derived: 10-K 9 month − 10-Q 6 month · filed 2018-03-08 | -$6.47M derived: sum of 2 quarters · filed 2018-03-08 | -$10.40M 10-K · filed 2018-03-08 | -$13.19M 10-K · filed 2018-03-08 | ||
| 2016-09-30 | -$2.18M 10-Q · filed 2017-11-02 | -$6.12M 10-Q · filed 2016-11-14 | -$8.90M 10-Q · filed 2017-11-02 | -$11.90M derived: sum of 4 quarters · filed 2017-11-02 | ||
| 2016-06-30 | -$3.93M 10-Q · filed 2017-08-09 | -$6.72M 10-Q · filed 2017-08-09 | -$9.72M derived: sum of 3 quarters · filed 2017-08-09 | -$12.39M derived: sum of 4 quarters · filed 2017-08-09 | ||
| 2016-03-31 | -$2.79M 10-Q · filed 2017-05-04 | -$2.79M 10-K · filed 2016-06-28 | -$5.79M derived: sum of 2 quarters · filed 2017-05-04 | -$8.45M derived: sum of 3 quarters · filed 2017-05-04 | -$15.06M 10-KT · filed 2017-03-13 | |
| 2015-12-31 | -$3.00M 10-K · filed 2016-06-28 | -$3.00M 10-Q · filed 2016-02-11 | -$5.66M derived: sum of 2 quarters · filed 2016-11-14 | -$12.27M 10-KT · filed 2017-03-13 | -$16.22M derived: sum of 4 quarters · filed 2016-11-14 | |
| 2015-09-30 | -$2.66M 10-Q · filed 2016-11-14 | -$9.27M 10-Q · filed 2016-11-14 | -$13.22M derived: sum of 3 quarters · filed 2016-11-14 | -$15.22M derived: sum of 4 quarters · filed 2016-11-14 | ||
| 2015-06-30 | -$6.61M 10-Q · filed 2016-08-15 | -$10.56M derived: sum of 2 quarters · filed 2016-08-15 | -$12.55M derived: sum of 3 quarters · filed 2016-08-15 | -$15.74M derived: sum of 4 quarters · filed 2016-08-15 | ||
| 2015-03-31 | -$3.95M derived: 10-K 12 month − 10-Q 9 month · filed 2016-06-28 | -$5.95M derived: sum of 2 quarters · filed 2016-06-28 | -$9.13M derived: sum of 3 quarters · filed 2016-06-28 | -$12.20M 10-K · filed 2016-06-28 | ||
| 2014-12-31 | -$2.00M 10-Q · filed 2016-02-11 | -$5.18M derived: sum of 2 quarters · filed 2016-02-11 | -$8.25M 10-Q · filed 2016-02-11 | -$9.69M derived: sum of 4 quarters · filed 2016-02-11 | ||
| 2014-09-30 | -$3.18M 10-Q · filed 2015-11-16 | -$6.25M 10-Q · filed 2015-11-16 | -$7.69M derived: sum of 3 quarters · filed 2015-11-16 | -$9.53M derived: sum of 4 quarters · filed 2015-11-16 | ||
| 2014-06-30 | -$3.07M 10-Q · filed 2015-08-06 | -$4.51M derived: sum of 2 quarters · filed 2015-08-06 | -$6.35M derived: sum of 3 quarters · filed 2015-08-06 | -$21.31M derived: sum of 4 quarters · filed 2015-08-06 | ||
| 2014-03-31 | -$1.44M derived: 10-K 12 month − 10-Q 9 month · filed 2015-05-19 | -$3.28M derived: sum of 2 quarters · filed 2015-05-19 | -$18.24M derived: sum of 3 quarters · filed 2015-05-19 | -$19.57M 10-K · filed 2015-05-19 | ||
| 2013-12-31 | -$1.84M 10-Q · filed 2015-02-05 | -$16.80M derived: sum of 2 quarters · filed 2015-02-05 | -$18.12M 10-Q · filed 2015-02-05 | |||
| 2013-09-30 | -$14.96M 10-Q · filed 2014-11-12 | -$16.28M 10-Q · filed 2014-11-12 | ||||
| 2013-06-30 | -$1.32M 10-Q · filed 2014-07-31 | |||||
| 2013-03-31 | -$6.38M 10-K · filed 2014-06-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |